27 October 2023 ORYZON reports financial results and corporate updates for quarter ended September 30, 2023
10 October 2023 ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder
3 October 2023 ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies
26 July 2023 Oryzon announces completed patient recruitment in the PORTICO Phase IIb trial of vafidemstat in Borderline Personality Disorder
24 July 2023 ORYZON reports financial results and corporate updates for half-year ending June 30, 2023
5 July 2023 Positive aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder